The U.S. Food and Drug Administration (FDA) has approved JOURNAVX (suzetrigine), Vertex Pharmaceuticals' oral, non-opioid, highly selective NaV1.8 pain signal inhibitor, for the treatment of adults with moderate-to-severe acute pain. This marks the first new class of pain medicine approved in over 20 years.
JOURNAVX offers an effective and well-tolerated pain relief option without evidence of addictive potential, addressing a critical unmet need in acute pain management. It is indicated for use across all types of moderate-to-severe acute pain.
Approximately 80 million people in the U.S. are prescribed medicine for moderate-to-severe acute pain annually, with about 40 million receiving an opioid. The wholesale acquisition cost for JOURNAVX is $15.50 per 50mg pill. Vertex has established patient support programs to ensure access for qualified patients.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.